Literature DB >> 6428426

[Light chain deposit disease: an anatomopathological entity].

C Hoffman-Guilaine, D Nochy, V Tricottet, L Mallet, J Bariety, J P Camilleri.   

Abstract

The light chain deposition disease was recently identified as a systemic clinicopathological entity characterized by amorphous extracellular deposits which differ from the amyloid substance. Various organs may be involved, notably the kidney, the liver, the myocardium and the skin. The histopathological aspects were investigated in 3 cases. By immunofluorescence using frozen sections the deposits were shown to contain monoclonal light kappa or lambda chains. By electron microscopy they appeared to be granular and usually located close to epithelial and/or vascular basal lamina. There was in every case a monoclonal lymphoplasmacytoid proliferation. In one case amyloid deposits were associated in small vessels. In another one, follow-up study after chemotherapy showed improvement of hepatomegaly, stabilization of renal function, and regression of light chain deposits in skin biopsy specimens.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428426

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  4 in total

1.  Light chain deposition disease neuropathy resembling amyloid neuropathy in a multiple myeloma patient.

Authors:  M P Grassi; F Clerici; C Perin; M Borella; A Gendarini; A Quattrini; R Nemni; A Mangoni
Journal:  Ital J Neurol Sci       Date:  1998-08

2.  Light chain deposition disease presenting with hepatomegaly: an association with amyloid-like fibrils.

Authors:  G Pelletier; M Fabre; P Attali; A Ladouch-Badre; O Ink; E Martin; J P Etienne
Journal:  Postgrad Med J       Date:  1988-10       Impact factor: 2.401

3.  Light chain deposition disease of the liver without renal involvement in a patient with multiple myeloma related to liver failure and rapid fatal outcome.

Authors:  Spyros Michopoulos; Kalliopi Petraki; Constantina Petraki; Meletios-Athanasios Dimopoulos
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

4.  Interferon-mediated reprogramming of membrane cholesterol to evade bacterial toxins.

Authors:  Quan D Zhou; Xun Chi; Min Sub Lee; Wei Yuan Hsieh; Jonathan J Mkrtchyan; An-Chieh Feng; Cuiwen He; Autumn G York; Viet L Bui; Eliza B Kronenberger; Alessandra Ferrari; Xu Xiao; Allison E Daly; Elizabeth J Tarling; Robert Damoiseaux; Philip O Scumpia; Stephen T Smale; Kevin J Williams; Peter Tontonoz; Steven J Bensinger
Journal:  Nat Immunol       Date:  2020-06-08       Impact factor: 25.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.